

**AMENDMENTS TO THE CLAIMS**

1.-6. (canceled)

7. (currently amended) A method for inhibiting or reducing transmigration of cells ~~such as leukocytes or tumor cells~~ comprising contacting said cells with a CD81 binding agent.

8. (currently amended) ~~[[A]] The method according to~~ of claim ~~[[7]]~~ 12, wherein said leukocytes are T lymphocytes or monocytes.

9. (currently amended) ~~[[A]] The method according to any one of claims 7-8~~ claim 8, wherein said contacting comprises administering an effective amount of said CD81 binding agent is ~~administered~~ to a mammal suffering from, or being at risk of developing, ~~[[()]]~~ tissue damage caused by~~[[D]]~~ an inflammatory disorder associated with leukocyte transmigration.

10. (currently amended) ~~[[A]] The method according to~~ of claim 9, wherein said disorder is selected from the group consisting of multiple sclerosis, stroke, spinal cord injury, traumatic brain injury, meningitis, Alzheimer's disease, Parkinson's disease, AIDS dementia, atherosclerosis, diabetes, inflammatory bowel disease, ~~(including Crohn's disease, and ulcerative colitis[[D]])~~, ischemia- reperfusion injury, ~~(including ischemic stroke, and myocard infarction[[D]])~~, rheumatoid arthritis, osteoarthritis, psoriasis, complications of tissue or organ transplantation including graft-versus-host and host-versus-graft disease.

11. (currently amended) ~~[[A]] The method according to any one of claims 7-8~~ claim 13, wherein said contacting comprises administering an effective amount of said CD81 binding agent is ~~administered~~ to a mammal suffering from, or being at risk of developing, tumor metastasis associated with transmigration of tumor cells.

12. (new) The method of claim 7, wherein the cells are leukocytes.

13. (new) The method of claim 7 wherein the cells are tumor cells.
14. (new) A method to treat or prevent tissue damage caused by an inflammatory disorder associated with leukocyte transmigration which method comprises administering to a subject in need of such treatment or prevention an effective amount of a CD81 binding agent.
15. (new) The method of claim 14, wherein said disorder is selected from the group consisting of multiple sclerosis, stroke, spinal cord injury, traumatic brain injury, meningitis, Alzheimer's disease, Parkinson's disease, AIDS dementia, atherosclerosis, diabetes, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ischemia- reperfusion injury, ischemic stroke, myocard infarction, rheumatoid arthritis, osteoarthritis, psoriasis, complications of tissue or organ transplantation including graft-versus-host and host-versus-graft disease.
16. (new) A method to treat or prevent tumor metastasis associated with transmigration of tumor cells which method comprises administering to a subject in need of such treatment or prevention an effective amount of a CD81 binding agent.